Meeting
2019 ASCO Annual Meeting
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
Authors
Michael E. Hurwitz
Yale School of Medicine, New Haven, CT
Michael E. Hurwitz , Daniel C. Cho , Arjun Vasant Balar , Brendan D. Curti , Arlene O. Siefker-Radtke , Mario Sznol , Harriet M. Kluger , Chantale Bernatchez , Christie Fanton , Ernesto Iacucci , Yi Liu , Tuan Nguyen , Willem Overwijk , Jonathan Zalevsky , Mary Ann Tagliaferri , Ute Hoch , Adi Diab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT02983045
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2623)
DOI
10.1200/JCO.2019.37.15_suppl.2623
Abstract #
2623
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
First Author: Nikhil I. Khushalani
Poster
2019 Genitourinary Cancers Symposium
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
First Author: Arlene O. Siefker-Radtke
Poster
2018 ASCO Annual Meeting
TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.
First Author: Jie Yu
Poster
2017 ASCO Annual Meeting
Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
First Author: Holger N. Lode